Literature DB >> 17318615

Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma.

Xiao-Li Du1, Hai Hu, De-Chen Lin, Shu-Hua Xia, Xiao-Ming Shen, Yu Zhang, Man-Li Luo, Yan-Bin Feng, Yan Cai, Xin Xu, Ya-Ling Han, Qi-Min Zhan, Ming-Rong Wang.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death in China. In the present study, proteins in tumors and adjacent normal esophageal tissues from 41 patients with ESCC were extracted, and two-dimensional electrophoresis (2-DE) was performed using the pH 3-10 and 4-7 immobilized pH gradient strips. The protein spots expressed differentially between tumors and normal tissues were identified by matrix-assisted laser desorption/ionization and liquid chromatography electrospray/ionization ion trap mass spectrometry. A total of 22 proteins differentially expressed between ESCC and normal esophageal tissues were identified, in which 17 proteins were upregulated and 5 downregulated in tumors. Biological functions of these proteins are related to cell signal transduction, cell proliferation, cell motility, glycolysis, regulation of transcription, oxidative stress processes, and protein folding. Some of the proteins obtained were confirmed by Western blotting and immunohistochemical staining. We showed that high expression of calreticulin and 78-kDa glucose-regulated protein (GRP78) were correlated with poor prognosis by Kaplan-Meier analysis and log rank analysis. Zinc finger protein 410, annexin V, similar to the ubiquitin-conjugating enzyme E2 variant 1 isoform c, mutant hemoglobin beta chain, TPM4-ALK fusion oncoprotein type 2, similar to heat shock congnate 71-kDa protein, GRP78, and pyruvate kinase M2 (M2-PK) were for the first time observed to be dysregulated in human ESCC tissues. The proteins here identified will contribute to the understanding of the tumorigenesis and progression of Chinese ESCC and may potentially provide useful markers for diagnosis or targets for therapeutic intervention and drug development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318615     DOI: 10.1007/s00109-007-0159-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   5.606


  58 in total

1.  Identification of differentially expressed proteins between human esophageal immortalized and carcinomatous cell lines by two-dimensional electrophoresis and MALDI-TOF-mass spectrometry.

Authors:  Xing-Dong Xiong; Li-Yan Xu; Zhong-Ying Shen; Wei-Jia Cai; Jian-Min Luo; Ya-Li Han; En-Min Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

2.  Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells.

Authors:  G L Prasad; E M Valverius; E McDuffie; H L Cooper
Journal:  Cell Growth Differ       Date:  1992-08

3.  Proteome analysis of human lung squamous carcinoma.

Authors:  Cui Li; Zhiqiang Xiao; Zhuchu Chen; Xiaopeng Zhang; Jianling Li; Xiaoying Wu; Xinying Li; Hong Yi; Maoyu Li; Guo Zhu; Songping Liang
Journal:  Proteomics       Date:  2006-01       Impact factor: 3.984

4.  Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade.

Authors:  M S Song; Y K Park; J H Lee; K Park
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 5.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

6.  Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK.

Authors:  Uma Kant Misra; Rohit Deedwania; Salvatore Vincent Pizzo
Journal:  J Biol Chem       Date:  2005-05-20       Impact factor: 5.157

7.  The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.

Authors:  K Koss; R F Harrison; J Gregory; S J Darnton; M R Anderson; J A Z Jankowski
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

8.  Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring.

Authors:  Joachim Schneider; Kathleen Neu; Helmut Grimm; Hans-Georg Velcovsky; Gunter Weisse; Erich Eigenbrodt
Journal:  Anticancer Res       Date:  2002 Jan-Feb       Impact factor: 2.480

9.  Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).

Authors:  H W Wechsel; E Petri; K H Bichler; G Feil
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

10.  Proteomic analysis of protein expression in prostate cancer.

Authors:  Helena Lexander; Carina Palmberg; Gert Auer; Magnus Hellström; Bo Franzén; Hans Jörnvall; Lars Egevad
Journal:  Anal Quant Cytol Histol       Date:  2005-10       Impact factor: 0.302

View more
  46 in total

1.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

Authors:  Chengwei Zhang; Xiao-Ran Han; Xiaobao Yang; Biao Jiang; Jing Liu; Yue Xiong; Jian Jin
Journal:  Eur J Med Chem       Date:  2018-03-27       Impact factor: 6.514

2.  Proteomics out of the archive: Two-dimensional electrophoresis and mass spectrometry using HOPE-fixed, paraffin-embedded tissues.

Authors:  Daniel Kähler; Christian Alexander; Holger Schultz; Mahdi Abdullah; Detlev Branscheid; Buko Lindner; Peter Zabel; Ekkehard Vollmer; Torsten Goldmann
Journal:  J Histochem Cytochem       Date:  2009-12-07       Impact factor: 2.479

3.  High Expression of GRP78 Promotes Invasion and Metastases in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Guohong Zhao; Jianqin Kang; Kai Jiao; Guanghui Xu; Lei Yang; Shanhong Tang; Hui Zhang; Ying Wang; Yongzhan Nie; Kaichun Wu; Daiming Fan; Hongbo Zhang; Dexin Zhang
Journal:  Dig Dis Sci       Date:  2015-05-15       Impact factor: 3.199

Review 4.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

Review 5.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

6.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.

Authors:  Manoj Kumar Kashyap; H C Harsha; Santosh Renuse; Harsh Pawar; Nandini A Sahasrabuddhe; Min-Sik Kim; Arivusudar Marimuthu; Shivakumar Keerthikumar; Babylakshmi Muthusamy; Kumaran Kandasamy; Yashwanth Subbannayya; Thottethodi Subrahmanya Keshava Prasad; Riaz Mahmood; Raghothama Chaerkady; Stephen J Meltzer; Rekha V Kumar; Anil K Rustgi; Akhilesh Pandey
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

7.  Protein and gene expression characteristics of heterogeneous nuclear ribonucleoprotein H1 in esophageal squamous cell carcinoma.

Authors:  Yu-Lin Sun; Fei Liu; Fang Liu; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

8.  Cellular transformation by cigarette smoke extract involves alteration of glycolysis and mitochondrial function in esophageal epithelial cells.

Authors:  Myoung Sook Kim; Yiping Huang; Juna Lee; Xiaoli Zhong; Wei-Wen Jiang; Edward A Ratovitski; David Sidransky
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

Review 9.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.